MX2021002077A - Nuevas composiciones de anticuerpos para la inmunoterapia contra el cáncer. - Google Patents

Nuevas composiciones de anticuerpos para la inmunoterapia contra el cáncer.

Info

Publication number
MX2021002077A
MX2021002077A MX2021002077A MX2021002077A MX2021002077A MX 2021002077 A MX2021002077 A MX 2021002077A MX 2021002077 A MX2021002077 A MX 2021002077A MX 2021002077 A MX2021002077 A MX 2021002077A MX 2021002077 A MX2021002077 A MX 2021002077A
Authority
MX
Mexico
Prior art keywords
cancer immunotherapy
antibody compositions
novel cancer
immunotherapy antibody
antibodies
Prior art date
Application number
MX2021002077A
Other languages
English (en)
Spanish (es)
Inventor
Chiang J Li
Shyam Unniraman
Hannah Bader
Mithilesh Jha
Original Assignee
1Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co Ltd filed Critical 1Globe Biomedical Co Ltd
Publication of MX2021002077A publication Critical patent/MX2021002077A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021002077A 2018-08-20 2019-08-20 Nuevas composiciones de anticuerpos para la inmunoterapia contra el cáncer. MX2021002077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862720015P 2018-08-20 2018-08-20
PCT/CN2019/101659 WO2020038379A1 (en) 2018-08-20 2019-08-20 Novel cancer immunotherapy antibody compositions

Publications (1)

Publication Number Publication Date
MX2021002077A true MX2021002077A (es) 2021-05-27

Family

ID=69591356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002077A MX2021002077A (es) 2018-08-20 2019-08-20 Nuevas composiciones de anticuerpos para la inmunoterapia contra el cáncer.

Country Status (12)

Country Link
US (1) US12391758B2 (cg-RX-API-DMAC7.html)
EP (1) EP3841126A4 (cg-RX-API-DMAC7.html)
JP (1) JP7488534B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210046725A (cg-RX-API-DMAC7.html)
CN (3) CN116063519B (cg-RX-API-DMAC7.html)
AU (1) AU2019324388A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003182A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110138A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021002077A (cg-RX-API-DMAC7.html)
SG (1) SG11202101757QA (cg-RX-API-DMAC7.html)
TW (1) TW202016150A (cg-RX-API-DMAC7.html)
WO (1) WO2020038379A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250223361A1 (en) * 2022-04-01 2025-07-10 Mabtree Biologics Ag Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function
CN118930652B (zh) * 2024-07-29 2025-03-11 北京肿瘤医院(北京大学肿瘤医院) 一种免疫检查点pd-l2靶向单链抗体及放射性核素标记物与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101704734B1 (ko) * 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CA2615460A1 (en) * 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
BR112014012819B1 (pt) * 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
EP2863947B1 (en) * 2012-06-21 2018-03-07 Sorrento Therapeutics, Inc. Antigen binding proteins that bind igf1r
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
CA3175360C (en) * 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
TW201639891A (zh) * 2015-03-10 2016-11-16 索倫多醫療公司 結合psma之抗體治療劑
CN114853891A (zh) 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN106432501B (zh) * 2015-08-06 2021-07-30 基石药业 新型抗pd-l1抗体
ES2986360T3 (es) * 2016-01-29 2024-11-11 Yuhan Corp Proteínas de unión a antígeno que se unen a PD-L1
US10059769B2 (en) * 2016-06-13 2018-08-28 I-Mab Anti-PD-L1 antibodies and uses thereof
CN106496327B (zh) * 2016-11-18 2019-01-15 昆山百尔泰生物科技有限公司 针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体
CN108239149B (zh) * 2016-12-25 2021-03-05 南京传奇生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体
CN107973854B (zh) * 2017-12-11 2021-05-04 苏州银河生物医药有限公司 Pdl1单克隆抗体及其应用
CA3117853A1 (en) * 2018-10-29 2020-05-07 1Globe Biomedical Co., Ltd. Novel rationally designed protein compositions

Also Published As

Publication number Publication date
CN116063519B (zh) 2026-04-28
SG11202101757QA (en) 2021-03-30
EP3841126A4 (en) 2022-08-10
BR112021003182A2 (pt) 2021-05-11
CN116063519A (zh) 2023-05-05
JP7488534B2 (ja) 2024-05-22
CN112839963A (zh) 2021-05-25
WO2020038379A1 (en) 2020-02-27
US12391758B2 (en) 2025-08-19
CA3110138A1 (en) 2020-02-27
KR20210046725A (ko) 2021-04-28
US20210332138A1 (en) 2021-10-28
CN112839963B (zh) 2023-02-10
CN116410320A (zh) 2023-07-11
TW202016150A (zh) 2020-05-01
JP2021534750A (ja) 2021-12-16
AU2019324388A1 (en) 2021-03-18
CN116410320B (zh) 2026-06-19
EP3841126A1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
PH12021551500A1 (en) Anti-ctla4 antibodies and methods of use thereof
EP4374926A3 (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
PH12022551298A1 (en) Antibodies specific for cd47, pd-l1, and uses thereof
EP3991748A3 (en) Anti-sortilin antibodies and methods of use thereof
MX2022002364A (es) Anticuerpos anti-pd-l1.
JOP20190236A1 (ar) أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد
WO2017220989A8 (en) ANTI-PD-L1 AND CYTOKINES IL-2
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
PH12018501611A1 (en) Antigen binding proteins thant bind pd-l1
NZ778865A (en) Novel anti-pd-1 antibodies
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
WO2020014473A8 (en) TGFβ1 INHIBITORS AND USE THEREOF
MX389090B (es) Anticuerpos anti-pd-l1 novedosos.
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
MX2021007848A (es) Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MA40526A (fr) Protéines de fixation antigénique fixant le cxcr3
MX2019009619A (es) Anticuerpo anti-cancer convertible de celula t regulatoria inducible por ifn-gamma (irtca) y usos del mismo.